Quick Answer
Rani Therapeutics Holdings, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
Rani Therapeutics Holdings, Inc. Long-Term Debt — Annual History
| Fiscal Year | Long-Term Debt | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $9.61M | -60.7% |
| 2023 | $24.48M | -16.0% |
| 2022 | $29.15M | — |
| 2021 | $0.00 | -100.0% |
| 2020 | $2.41M | — |
Quarterly Long-Term Debt
| Quarter Ending | Long-Term Debt | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $0.00 | -100.0% | -100.0% |
| June 30, 2025 | $2.23M | -87.0% | -62.4% |
| March 31, 2025 | $5.92M | -71.6% | -38.4% |
| December 31, 2024 | $9.61M | -60.7% | -29.0% |
| September 30, 2024 | $13.54M | -51.8% | -21.3% |
| June 30, 2024 | $17.21M | -41.2% | -17.5% |
| March 31, 2024 | $20.85M | -28.6% | -14.8% |
| December 31, 2023 | $24.48M | -16.0% | -12.9% |
- Rani Therapeutics Holdings, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- Over the 2020–2025 period, Rani Therapeutics Holdings, Inc.’s long-term debt has declined by 100.0% (from $2.41 million to $0.00).
- The most recent figure is from Rani Therapeutics Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: